Skip to main content
. 2018 Sep 25;9(75):34090–34102. doi: 10.18632/oncotarget.26124

Figure 4. PDGF-PDGFRβ signaling does not affect the differentiation of mesenchymal stem cells into cancer-associated fibroblasts.

Figure 4

(A) Lysates of ST2 cells treated with PDGF-BB (20 ng/mL) for 15 min, 1 h, or 6 h were subjected to western blotting with anti-p-PDGFRβ, anti-p-tyrosine, anti-PDGFRβ, and anti-GAPDH antibodies. (B, C) Quantitative RT-PCR analyses were performed to measure mRNA expression of αSMA (B) and TGFβ (C) in ST2 cells treated with PDGF-BB for 48 h. Each bar represents the mean ± SD (N=3). (D) ST2 cells were pre-treated with CP673451 (50 nM) for 2 h and then stimulated with PDGF-BB for 15 min or 1 h. Cell lysates were subjected to western blotting with anti-p-PDGFRβ, anti-PDGFRβ, and anti-GAPDH antibodies. (E) ST2 cells were pre-treated with CP673451 for 1 h and then stimulated with TGFβ (10 ng/mL) for 3 days. Quantitative RT-PCR analysis was performed to measure mRNA expression of αSMA. Each bar represents the mean ± SD (N=3). (F) Lysates of ST2 cells stimulated with TGFβ for 15 min, 1 h, or 6 h were subjected to western blotting with anti-p-PDGFRβ, anti-p-tyrosine, anti-PDGFRβ, and anti-GAPDH antibodies.